Altasciences continues to beef up its exec suite with newly promoted CMO

Canadian pharmaceuticals
(Shutterstock)

The Canadian biopharma services company Altasciences has promoted Dr. Gaetano Morelli as its new chief medical officer.

Dr. Morelli has been at Altasciences in various guises for seven years, first as a a GI consultant and then signing on as medical advisor back in in 2017, climbing up the ladder until hitting the CMO role.

In his new role, he “will continue to provide key insight to our teams in North America and to sponsors worldwide as we navigate the complexities of early-phase drug development,” said Chris Perkin, Altascience’s CEO.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Before Altasciences, Dr. Morelli was the global medical director at MDS Pharma for 10 years, and is also an Associate Professor of Medicine at McGill University in Montreal.

It comes amid a few changes at the top of its medical side of the business over the past year or so, with CRO veteran Beatrice Setnik, Ph.D., becoming its new chief scientific officer last August, followed by its hiring of Lynne LeSauteur, Ph.D., as its VP of immunochemistry and immunology a month later.

Back in 2018, the company penned a new deal that saw it snap up the preclinical testing business of SNBL USA.

Read more on

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.